Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Plasma 1,3-β-d-glucan levels predict adverse clinical outcomes in critical illness
Georgios D. Kitsios, … , Bryan J. McVerry, Alison Morris
Georgios D. Kitsios, … , Bryan J. McVerry, Alison Morris
Published June 15, 2021
Citation Information: JCI Insight. 2021;6(14):e141277. https://doi.org/10.1172/jci.insight.141277.
View: Text | PDF
Clinical Medicine Infectious disease Microbiology

Plasma 1,3-β-d-glucan levels predict adverse clinical outcomes in critical illness

  • Text
  • PDF
Abstract

BACKGROUND The fungal cell wall constituent 1,3-β-d-glucan (BDG) is a pathogen-associated molecular pattern that can stimulate innate immunity. We hypothesized that BDG from colonizing fungi in critically ill patients may translocate into the systemic circulation and be associated with host inflammation and outcomes.METHODS We enrolled 453 mechanically ventilated patients with acute respiratory failure (ARF) without invasive fungal infection and measured BDG, innate immunity, and epithelial permeability biomarkers in serially collected plasma samples.RESULTS Compared with healthy controls, patients with ARF had significantly higher BDG levels (median [IQR], 26 pg/mL [15–49 pg/mL], P < 0.001), whereas patients with ARF with high BDG levels (≥40 pg/mL, 31%) had higher odds for assignment to the prognostically adverse hyperinflammatory subphenotype (OR [CI], 2.88 [1.83–4.54], P < 0.001). Baseline BDG levels were predictive of fewer ventilator-free days and worse 30-day survival (adjusted P < 0.05). Integrative analyses of fungal colonization and epithelial barrier disruption suggested that BDG may translocate from either the lung or gut compartment. We validated the associations between plasma BDG and host inflammatory responses in 97 hospitalized patients with COVID-19.CONCLUSION BDG measurements offered prognostic information in critically ill patients without fungal infections. Further research in the mechanisms of translocation and innate immunity recognition and stimulation may offer new therapeutic opportunities in critical illness.FUNDING University of Pittsburgh Clinical and Translational Science Institute, COVID-19 Pilot Award and NIH grants (K23 HL139987, U01 HL098962, P01 HL114453, R01 HL097376, K24 HL123342, U01 HL137159, R01 LM012087, K08HK144820, F32 HL142172, K23 GM122069).

Authors

Georgios D. Kitsios, Daniel Kotok, Haopu Yang, Malcolm A. Finkelman, Yonglong Zhang, Noel Britton, Xiaoyun Li, Marina S. Levochkina, Amy K. Wagner, Caitlin Schaefer, John J. Villandre, Rui Guo, John W. Evankovich, William Bain, Faraaz Shah, Yingze Zhang, Barbara A. Methé, Panayiotis V. Benos, Bryan J. McVerry, Alison Morris

×

Figure 2

Mechanically ventilated patients with acute respiratory failure had higher BDG levels compared with inpatients with COVID-19 and healthy controls and lower levels compared with patients with traumatic brain injury.

Options: View larger image (or click on image) Download as PowerPoint
Mechanically ventilated patients with acute respiratory failure had high...
The conventional threshold of 60 pg/mL in the diagnostic workup of invasive fungal infection is shown with a red dashed line, distinguishing 81% of patients with acute respiratory failure with negative BDG levels versus 19% with intermediate or positive levels. We used published raw data for BDG values in healthy control groups. Displayed P values for comparisons of BDG levels between the discovery and validation cohorts were derived from nonparametric Wilcoxon’s tests, whereas for the comparison with healthy controls, we constructed mixed linear regression models with random study intercepts to account for potentially different BDG levels by study. Median and IQR BDG values by group are shown. ***P < 0.001; ****P < 0.0001.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts